trending Market Intelligence /marketintelligence/en/news-insights/trending/Rx24CqUaRqd7kWMeUeMNhw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

S&P cuts Endo International's corporate credit rating to B from B+

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


S&P cuts Endo International's corporate credit rating to B from B+

S&P Global Ratings downgraded Endo International plc's corporate credit rating to B from B+.

The outlook on the ratings is stable.

According to the rating agency, Endo's businesses are being negatively affected by continued generic pricing pressures and increased scrutiny on opioid prescriptions. The rating on Endo is also supported by the increased scale from the Par acquisition, product diversification and research and development capabilities in the competitive generic pharmaceutical market.

S&P said the stable outlook reflects expected lower revenue and EBITDA over the next year due to continued price erosion, lower market shares and asset divestitures.

S&P Global Ratings and S&P Global Market Intelligence are owned by S&P Global Inc.